DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Roche - 1 tiragolumab - 1 Morgan - 1 Roche's - 1 TIGIT - 1 Paul Arnold - 1 Christy Santhosh - 1 Jason Neely - 1
Top related locs:
U.S Zurich Bengaluru
Top related orgs:
Merck & Co - 1 Gilead Sciences - 1 iTeos Therapeutics - 1 Arcus Biosciences - 1 Thomson - 1

Search resuls for: "TIGIT"


3 mentions found


☆ Roche inadvertently publishes positive interim trial data on lung cancer drug
  + stars: | 2023-08-23 | by ( Ludwig Burger Rachel More | Ludwig Burger | Rachel More | ) www.reuters.com   time to read: +2 min
BERLIN, Aug 23 (Reuters) - Roche (ROG.S) inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker's shares even though more data will be needed to confirm the treatment's efficacy. Roche said on Wednesday that market participants had made it aware of the inadvertent disclosure of an interim data analysis on new immunotherapy tiragolumab, part of an experimental class of drugs known as anti-TIGIT. The data lifted Roche shares by 5% and sent shares of other companies testing anti-TIGIT drugs higher. J.P. Morgan analysts said the interim data suggested a survival benefit was within reach in the final analysis, but the clinical relevance remained uncertain. The unintended disclosure regards the second interim analysis of a Phase III trial known as Skyscraper 1.
Persons: Roche, tiragolumab, Morgan, Roche's, TIGIT, Paul Arnold, Christy Santhosh, Jason Neely, Friederike Heine, Mark Potter Organizations: Merck & Co, Gilead Sciences, iTeos Therapeutics, Arcus Biosciences, Thomson Locations: U.S, Zurich, Bengaluru
☆ Biotech investor Brad Loncar shares 10 predictions for 2023, including a hot new cancer target, Nobel Prize winners, and a biotech founder running for president
  + stars: | 2023-01-04 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +14 min
Loncar shared his 2023 forecast, including new drugs, Nobel Prize winners, and more globalization. Brad Loncar isn't expecting a miraculous rebound for the biotech industry in 2023. In an interview with Insider, Loncar shared 10 predictions for biotech in 2023, ranging from Nobel Prize winners and presidential runs to hot cancer targets and bankruptcy worries. 2022 was a rough year for the biotech industry, which once again underperformed the stock market. The industry runs to the next super-hot cancer target: Claudin 18.2In cancer research, drug companies are always on the hunt for the next promising target.
☆ A top Wall Street analyst names 6 major events that could send biotech stocks soaring between now and the end of 2022
  + stars: | 2022-11-14 | by ( Yeji Jesse Lee | ) www.businessinsider.com   time to read: +5 min
Cantor Fitzgerald analysts named six big events to mark on your calendar. While the majority of the expected events are set to come from smaller biotech companies, bigger companies — like Roche, Gilead, and Alnylam — have their own events coming through the pipeline. Here are the six major events from big biotech companies that could send stocks soaring:1. Cantor Fitzgerald analysts give Gilead's stock a neutral rating and they have an overweight rating on Arcus. Lenacapavir "could become a much bigger piece of the HIV growth narrative over the next few years," according to Cantor Fitzgerald analysts.
0 next >>
Total: 3